Re-biopsy in a patient with IgA nephropathy showing success of treatment with cyclosporin A and angiotensin-II receptor blocker

Clinical and Experimental Nephrology

Volumn 6, Issue 3, 2002, Pages 166-169

  Machiguchi, Toshihiko ^a   Tei, Masahiko ^a   Ono, Takahiko ^b   Kambara, Hirofumi ^a  

^a OSAKA RED CROSS HOSPITAL   (Japan)

^b KYOTO UNIVERSITY   (Japan)

Author keywords

Angiotensin II receptor blocker; Cyclosporin A; IgA nephropathy; Nephrotic syndrome

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; CANDESARTAN; CYCLOSPORIN A; IMMUNOGLOBULIN A;

ADULT; ARTICLE; CASE REPORT; CREATININE BLOOD LEVEL; DRUG EFFICACY; HISTOLOGY; HUMAN; IMMUNOGLOBULIN A NEPHROPATHY; IMMUNOGLOBULIN DEPOSITION; KIDNEY BIOPSY; KIDNEY FUNCTION; KIDNEY INJURY; MALE; NEPHROTIC SYNDROME; PROTEIN URINE LEVEL; PROTEINURIA; TREATMENT OUTCOME;

EID: 0036710860     PISSN: 13421751     EISSN: None     Source Type: Journal    
DOI: 10.1007/s101570200029     Document Type: Article

References (21)

1. Tojo S, Narita M, Koyama T, Miyahara T, Nagasawa T, Kitagawa T, et al. Clinical evaluation of ciclosporin in the treatment of nephrotic syndrome; a multi-center double blind study (in Japanese). Kidney and Dialysis. Tokyo: Tokyo Igakusha. 1994;37:565-608.
2. Cattran DC. Use of cyclosporin in membranous and mesangio- proliferative (IgA) nephropathy. In: Tejani A, editor. Cyclosporin in the therapy of renal disease (Contributions to Nephrology, vol. 114). Basel: Karger; 1995. p. 49-58.
3. Chábová V, Tesar V, Zabka J, Rychlik I, Merta M, Jirsa M Jr, Stejskalova A. Long term treatment of IgA nephropathy with cyclosporine A. Renal Failure 2000;22:55-62.
4. Perico N, Remuzzi A, Sangalli F, Azzollini N, et al. The antiproteinuric effect of angiotensin antagonism in human IgA nephropathy is potentiated by indomethacin. J Am Soc Nephrol 1998;9:2308-17.
5. Russo D, Minutolo R, Pisani A, Esposito R, et al. Coadministration of losartan and enalapril exerts additive antiproteinuric effect in IgA nephropathy. Am J Kidney Dis 2001;38:18-25.
6. Falk RJ, Jennette JC, Nachman PH. IgA Nephropathy. In: Brenner BM, editor. The kidney. 6th Ed. Philadelphia: WB Saunders; 2000. p.1302-9.
7. Yoshikawa N, Tanaka R, Iijima K. Pathophysiology and treatment of IgA nephropathy in children. Pediatr Nephrol 2001;16:446-57.
8. Ambalavanan S, Fauvel JP, Sibley RK, Myers BD. Mechanism of the antiproteinuric effect of cyclosporine in membranous nephropathy. J Am Soc Nephrol 1996;7:290-8.
9. Berden JHM, Schrijver G, Desassis JF, van der Born J. Cyclosporine A (CsA) in experimental models of proteinuria. Mechanism of the antiproteinuric effect. XIIth International Congress of Nephrology. Jerusalem. Book of Abstracts 1993;534.
10. Martin M, Neumann D, Hoff T, Resch K, DeWitt DL, Goppelt-Struebe M. Interleukin-1-induced cyclooxygenase 2 expression is suppressed by cyclosporin A in rat mesangial cells. Kidney Int 1994;45:150-8.
11. Losa Garcia JE, Rodriguez Lopez AM, Martin De Cabo MR, et al. Cyclosporin A decreases human macrophage interleukin-6 synthesis at post-transcriptional level. Mediators Inflammation 1999;8: 253-9.
12. Yard BA, Pancham RR, Paape ME, Daha MR, et al. CsA, FK506, corticosteroids and rapamycin inhibit TNFα production by cultured PTEC. Kidney Int 1993;44:352-8.
13. Lai KN, Lam CWK, Cheng IKP, Tam JSL, Lai FM. Effect of cyclosporin A on circulating immune complexes in IgA nephropathy. Int Urol Nephrol 1991;23:265-74.
14. Lai KN, Lai FM, Li PL. Vallance-Owen J. Cyclosporin treatment of IgA nephropathy: A short-term controlled trial. BMJ 1987;295: 1165-8.
15. Schena FP, Mastrolitti G, Jirillo E, Munno I, Pellegrino N, Fracasso AR, Aventaggiato I. Increased production of interleukin-2 and IL-2 receptor in primary IgA nephropathy. Kidney Int 1989;35:875-9.
16. Chung WY, Lim IS, Lee SY, Lee SK. Immunologic and morphologic study of experimental IgA nephropathy in ddY mice after administration of cyclosporin A (CyA) (abstract). Kidney Int 1992;41:1952-3.
17. Kobayashi M, Kobayashi Y, Kobayashi N, Tanaka H, Sano T, Tagawa T. Clinical and histological improvement with long-term, low-dose cyclosporin A in a patient with severe IgA nephropathy. Clin Exp Nephrol 2001;5:126-30.
18. Remuzzi G, Bertani T. Renal vascular and thrombotic effects of cyclosporine. Am J Kidney Dis 1989;13:261-72.
19. Gibson J, Bleasel A, Duggin G, Joshua D, et al. Cyclosporine A-associated proteinuria. Med J Aust 1987;146:325.
20. Mason J. Renal side-effects of cyclosporin A. Br J Dermatol 1990;122(Suppl 36):71-7.
21. Lee DBN. Cyclosporine and renin-angiotensin axis. Kidney Int 1997;52:248-60.